04
Sep
#HealthMinistry #NDCTRules #ClinicalTrials #PharmaIndia #EaseOfDoingBusiness #DrugDevelopment #ClinicalResearch #BA_BEStudies #ModiGovernment #PharmaGrowth New Delhi – In a significant step towards regulatory reform and ease of doing business, the Union Health Ministry has announced amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at simplifying procedures for test licence applications and bioavailability/bioequivalence (BA/BE) study approvals. The proposed amendments, published in the Gazette of India on August 28, 2025, are now open for public comments before their final adoption. The move comes under the direction of Prime Minister Narendra Modi, who has emphasized reducing compliance burdens and promoting India as a global…